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Abstract
Background: The purpose of this observational study was to evaluate feasibility, efficacy results and toxicity
observations of capecitabine in routine first line treatment of patients with metastatic colorectal cancer, with
particular regard of elderly patients (>75 years of age).
Methods: Patients with colorectal cancer receiving capecitabine as part of their first-line treatment were recorded
until detection of disease progression or up to a maximum of 12 cycles on standardized evaluation forms.
Additional information on long-term outcomes, progression-free survival, and overall survival were retrieved at two
follow-up time points. Obtained data were analyzed with regard to age up to 75 and >75 years of age. There were
no specific requirements for patient selection and conduct of therapy, corresponding to the non-interventional
nature of the study.
Results: In total, 1249 evaluable patients were enrolled in Germany. The median age of the study population was
74 years (range: 21–99). Capecitabine-based combination was administered in 56 % of patients in the overall
population. The median treatment duration was about 5 months. Severe toxicities occurred rarely without any
difference regarding age groups. The most common hematological toxicity was anemia. Gastrointestinal side effects
and hand-food-syndrome (HFS) were the most frequent non-hematologic toxicities. Overall response rate (ORR) was
significantly higher in the patient group <=75 years compared to patients >75 years of age (38 vs. 32 %, p=0.019).
Median progression free survival (PFS 9.7 vs. 8.2 months, p=0.00021) and overall survival (OS 31.0 vs. 22.6 months,
p<0.0001) was decreased in elderly patients.
Conclusion: Efficacy and tolerability of capecitabine treatment either as single drug or in various combination
regimens, as proven in randomized studies, could be confirmed in a clinical routine setting. Patients older than
75 years may derive a relevant benefit by first line capecitabine-based treatment with good tolerability.
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Background
While, for more than four decades, the treatment of
colorectal cancer (CRC) consisted almost exclusively of
the fluoropyrimidine 5-fluorouracil (5-FU) (eventually
modulated by folinic acid or levamisole), the develop-
ment of a plethora of new drugs since the 1990s has
improved the therapeutic options in this indication.
In addition to new agents with a classical cytotoxic
mode of action, such as irinotecan and oxaliplatin,
“targeted therapies”, such as monoclonal antibodies,
tyrosine kinase inhibitors or fusion proteins directed
against vascular endothelial growth factors (receptors)
(VEGF(R)) or epidermal growth factor receptors (EGFR)
have gained increasing importance [1, 2].
Administration of 5-FU, the main chemotherapy
backbone in metastatic CRC (mCRC), is confined to
either implanted venous access ports or in-patient
treatment. Thus, the development of capecitabine, an
oral fluoropyrimidine carbamate working as 5-FU pro-
drug, relevantly facilitated treatment for CRC patients.
Capecitabine (Xeloda®) was licensed for the treatment
of metastatic colorectal cancer mainly based on two
large multicenter studies, both comparing the oral
drug with a common 5-FU/leucovorin combination
(Mayo regimen) [3, 4]. Following trials could establish
the combination with oxaliplatin or irinotecan, and/or
bevacizumab although particularly the combination of
capecitabine and irinotecan has shown gastrointestinal
side effects, which have to be closely monitored [5–10].
Currently, even chemotriplets with capecitabine, irino-
tecan and oxaliplatin with or without bevacizumab
are being evaluated [11, 12]. Despite the long-
standing application of capecitabine in the treatment
of colorectal cancer, data in elderly patients are still
limited.
The purpose of this non-interventional observation
study was the acquisition of data on the routine usage of
capecitabine, its efficacy and toxicity spectrum in routine
clinical practice with particular focus on the benefit in
patients >75 years of age.
Methods
The project fulfilled the criteria of a non-interventional
study according to the European Community and German
legislation, and therefore required neither an ethical com-
mittee vote nor informed consent of the patients when
the registry was started in 2004 [13]. In order to achieve a
representative picture of capecitabine use in Germany,
participation was offered to a large variety of office or
hospital-based medical oncologists or gastroenterologists.
Recruitment was limited to a pre-specified number of
cases per investigator. The per patient-documentation fee
was independent of the number of cycles documented. To
ensure enrolment of a typical advanced CRC population,
eligibility criteria were minimized to age ≥18 years, histo-
logically confirmed advanced (metastatic or inoperable,
locally advanced or recurrent) colorectal cancer without
prior palliative treatment and eligibility for capecitabine
treatment based on the summary of product characteris-
tics. Treatment regimen (combination), diagnostics or fre-
quency of examinations were scheduled by the respective
treating hospital and office based clinicians. The applied
dosage, treatment duration, cycle delays and/or therapy
interruptions and eventually concomitant antineoplastic
therapy were investigated in addition to demographic and
baseline characteristics. Efficacy endpoints were overall re-
sponse rate (ORR), PFS and OS. Tumor regression and
progressive disease was recorded as the best response
achieved, based on standard clinical procedures at the dis-
cretion of the investigators, without formal requirement of
objective remission confirmation. Toxicity data were re-
corded after every second cycle (6 weeks), based on NCI
CTC (National Cancer Institute Common Terminology
Criteria for Adverse events) criteria (version 2). The de-
tailed documentation was performed to a maximum of
12 cycles or until progression. Thereafter, key long-term
data on overall survival and progression-free survival were
retrieved by fax forms at two time points in 2010 and
2012.
The statistical methods were mainly descriptive.
Most of the analyses presented were performed separ-
ately for the patient subgroups aged ≤75 and
>75 years, respectively. Patients beyond 75 years of
age are henceforward defined as “older” within this
report. Capecitabine dosages were calculated individu-
ally, based on the reported absolute dose and the
body surface of the patient. To compare baseline
characteristics, and the response or toxicity rates in
different patient groups, a Mantel-Haenszel test for
trend or Fisher’s exact test was applied. PFS was defined
from the first day of therapy with capecitabine to disease
progression or death from any reason without prior pro-
gression. The PFS and OS curves were calculated accord-
ing to the Kaplan-Meier method [14] and between-group
comparisons were performed using the logrank test [15].
Results
Baseline characteristics
Between 2004 and 2011 altogether 1305 German pa-
tients were recruited of whom 1249 patients with ad-
vanced colorectal cancer were eligible for the evaluation.
The majority of patients (60 %) were recruited in the
second half of the period (between 2008 and 2011).
Table 1 provides a description of the study population
and their baseline tumor characteristics. A considerable
number of older patients participated in this non-
interventional trial shown by a median age of the study
population of 74 years. At the start of therapy the ECOG
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(Eastern Cooperative Oncology Group) performance
status was not impaired (grade 0 in 28 %) or only
slightly reduced (grade 1 in 52 %) in the majority of
patients. Performance status in older patients was
limited compared to patients up to the age of 75 years
(p <0.0001). In 47 % of patients locoregional disease
was present at study entry. Synchronous metastatic
disease was reported in 646 patients. In the 541 patients
with metachronous metastases the median relapse-free
interval, defined as the time between first diagnosis of the
disease and first detection of metastases was 1.6 years.
Nearly two thirds (64 %) of the patients suffered from liver
metastases and 29 % from lung involvement with the
latter occurring significantly less frequently in older
patients (p = 0.0057). Bone and central nervous system
(CNS) lesions, pleural effusion and ascites occured
rarely with an incidence of below 5 % each. Almost
all patients (89 %) received initial surgery of their
primary tumor, interestingly with no differences re-
garding age. Radiotherapy was applied in 15 % of the
patients with a significantly decreasing proportion in
older patients (p <0.0001). Overall 252 (30 %) patients
received prior chemotherapy for non-metastatic dis-
ease (neo-/adjuvant). Chemotherapeutic pretreatment
was more common in younger patients with a continuous
and significantly decreasing percentage with age (37 % in
patients younger than 76 years compared to 19 % in pa-
tients beyond 75 years; p <0.0001). Median time between
Table 1 Patient and tumor characteristics
No. of patients (%) ≤75 years 711 (57 %) >75 years 538 (43 %) Total 1249 (100 %)
Age,median (range), years 74 (21–99)
Sex, no. of patients (%)
Male 418 (59 %) 266 (49 %) 684 (55 %)
Female 293 (41 %) 272 (51 %) 565 (45 %)
ECOG performance, no. of patients (%)
0 224 (32 %) 111 (22 %) 335 (28 %)
1 350 (50 %) 281 (55 %) 631 (52 %)
2 107 (15 %) 105 (20 %) 212 (18 %)
3 12 (2 %) 18 (3 %) 30 (2 %)
4 1 (0 %) 0 (0 %) 1 (0 %)
Grading, no. of patients (%)
G0/G1 23 (3 %) 15 (3 %) 38 (4 %)
G2 413 (62 %) 323 (66 %) 736 (64 %)
G3 201 (30 %) 129 (26 %) 330 (29 %)
GX 27 (4 %) 21 (4 %) 48 (4 %)
Disease site at entry, no. of patients (%)a
Local 325 (46 %) 259 (48 %) 584 (47 %)
Liver 453 (64 %) 352 (65 %) 805 (64 %)
Lung 230 (32 %) 135 (25 %) 365 (29 %)
Bone 30 (4 %) 24 (4 %) 54 (4 %)
CNS 6 (1 %) 2 (0 %) 8 (1 %)
Pleural effusion 16 (2 %) 9 (2 %) 25 (2 %)
Ascites 21 (3 %) 24 (4 %) 45 (4 %)
Other 151 (21 %) 95 (18 %) 246 (20 %)
Relapse-free intervalb, median, years n = 541 patientsc 1.8 1.5 1.6
M1 at initial diagnosis, no. of patients (%)n = 1066 patientsc 367 (59 %) 279 (63 %) 646 (61 %)
Previous surgery, no. of patients (%)n = 1248 patientsc 626 (88 %) 480 (89 %) 1106 (89 %)
Previous radiotherapy, no. of patients (%)n = 1239 patientsc 137 (19 %) 53 (10 %) 190 (15 %)
Previous (neo) adjuvant chemo- therapy, no. of patients (%)n = 847 patientsc 187 (37 %) 65 (19 %) 252 (30 %)
athe choice of multiple categories was possible
bpatients with metachronous metastases only
cevaluable patients for the respective parameter
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the end of prior chemotherapy and initiation of systemic
treatment for advanced disease and thus beginning of the
observation period was 1 year. In 27 % of these patients
the interval was longer than 2 years.
Treatment
580 patients (46 %) received single agent capecitabine,
the other 668 patients (54 %) were treated with capecita-
bine in combination with one (39 %) or two (15 %)
additional drugs (Table 2). The most frequently used
concomitant drugs were oxaliplatin (43 %), bevacizumab
(36 %) and irinotecan (17 %). Only 27 patients (4 %) re-
ceived capecitabine in combination with EGFR anti-
bodies. Single agent capecitabine was predominantly
administered in the group of patients aged over 75 years
(65 %) and in almost three out of four patients older
than 85 years (74 %). Notably, the rates of oxaliplatin-
based combinations were significantly lower in older pa-
tients (only 15 % of patients >75 years; p <0.0001).
The median treatment duration with capecitabine was
5.3 months. Only 8 % of patients received capecitabine
for more than 10 months. In general, treatment duration
tended to be independent of patients’ age with medians
of 5.3 months in both age cohorts. The overall median
daily dose of capecitabine was 1727 mg/m2 with only
very small difference between the two age groups
(1744 mg/m2 for younger and 1702 mg/m2 for elderly
patients). For the monotherapy the observed median
dose of capecitabine was 1838 mg/m2. As to be ex-
pected, the dosage was lower when combination chemo-
therapy was given (1635 mg/m2), with medians between
1300 and 1777 mg/m2 depending on the type of combin-
ation regimen (Additional file 1: Table S1).
Treatment courses were delayed in only 13 % of all cy-
cles, but nevertheless occurred at least once in 54 % of
patients. Capecitabine dose reductions were reported in
22 % of all cycles and 45 % of all patients, respectively.
In terms of treatment discontinuation, no distinct
difference could be observed regarding age whereas dose
reduction occurred more often in younger patients,
likely related to the higher rate of combination regimen
(p = 0.040).
In 663 patients (53 %) the observation was terminated
according to the observation plan, either due to progres-
sive disease (58 %) or due to reaching the maximum
documentation period of 12 cycles (42 %). In the
remaining 580 patients (47 %), reasons for a premature
termination of the treatment were side effects (23 %),
patient’s wish/non-compliance (15 %) and death due to
the underlying disease (11 %). Other reasons (52 %)
mainly were an a priori planned number of cycles of less
than 12 or the achievement of a good response.
Toxicity
Table 3 shows the hematological and non-hematological
adverse events according to age groups (split by median
age) and combination vs. monotherapy. The NCI toxicity
grade per patient was pre-specified in the observation
forms. Regardless of age, severe hematological and non-
hematological toxicities (grade 3 or 4) occurred only
rarely, despite the high rate of combination regimens ap-
plied (54 % of patients). The most common toxicities
were gastrointestinal disorders like nausea, diarrhea or
vomiting, as well as hand-foot-syndrome (HFS) occur-
ring in 42 % of the patients. Expectedly, oxaliplatin-
based compared to irinotecan-based regimen showed
different rates of all grade thrombocytopenia (33 % vs.
11 %), diarrhea (40 % vs. 49 %), alopecia (21 % vs. 41 %)
and neurological disorders (21 % vs. 11 %), respectively.
The proportion of patients affected by HFS increased
with the duration of the treatment. In cycles 1 and 2,
HFS occurred in only 15 % of the patients, increasing to
27 % in cycles 3 and 4, 32 % in cycles 5 and 6 and finally
39 % in cycles 7 and 8. Despite similar median daily
dosage of capecitabine, all grade HFS was more frequent
in younger patients (46 %) compared to only 37 % in
Table 2 Type of regimens
Regimens ≤ 75 years >75 years Total
n 710 538 1248
Capecitabine (mono) 232 (33 %) 348 (65 %) 580 (46 %)
Capecitabine + 1 cytostatic/antibody 312 (44 %) 169 (31 %) 481 (39 %)
Capecitabine + 2 cytostatics/antibodies 166 (23 %) 21 (4 %) 187 (15 %)
Capecitabine + Irinotecan 31 (4 %) 22 (4 %) 53 (4 %)
Capecitabine + Oxaliplatin 186 (26 %) 82 (15 %) 268 (21 %)
Capecitabine + antibody 87 (12 %) 64 (12 %) 151 (12 %)
Capecitabine + Irinotecan + antibody 80 (11 %) 7 (1 %) 87 (7 %)
Capecitabine + Oxaliplatin + antibody 80 (11 %) 10 (2 %) 90 (7 %)
Capecitabine + other combination 14 (2 %) 5 (1 %) 19 (2 %)
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patients older than 75 years (p = 0.0014). However, the
rates of grade 3/4 HFS were similar in both age groups
(Table 3).
Treatment efficacy
1237 patients were evaluable for objective tumor re-
sponse (Table 4). 35 % of these achieved an objective re-
mission (complete in 6 % and partial in 29 %), with rates
decreasing from 38 % to 32 % in the respective age co-
horts (p = 0.019). For the evaluation of the parameters
PFS and OS 1245 patients could be included. The
Kaplan-Meier estimate of PFS, based on 881 events in
1245 patients (71 %) showed a median of 9.2 months for
the whole observation group (Additional file 2: Figure
S1). Median PFS in elderly patients was significantly de-
creased with 8.2 months, compared to 9.7 months in pa-
tients up to 75 years of age (p = 0.00021, HR = 1.29, 95 %
CI 1.13–1.47) (Fig. 1). In comparison to single drug cap-
ecitabine with a median PFS of 8.3 months, a non-
significant difference towards an improved PFS with me-
dian 9.8 months could be observed for the combination
regimen (p = 0.063, HR = 0.88, 95 % CI 0.77–1.01). For
497 (40 %) out of 1245 patients the date of death was
documented, resulting in an overall median OS of
26.1 months. In elderly patients OS was significantly de-
creased (median 22.6 months), compared to 31.0 months
in patients up to 75 years of age (p < 0.0001, HR = 1.61,
95 % CI 1.35–1.92) (Fig. 2). In contrast, the comparison
of regimen types (single agent vs. combination) showed
no differences in terms of OS (25.9 vs. 26.1 months,
p = 0.71, HR = 0.97, 95 % CI 0.81–1.15).
Patients suffering from HFS of any grade during therapy
had a higher response rate (43 %) than patients without
this symptom (31 %) (p < 0.0001). Moreover, PFS and OS
were significantly prolonged in patients who experienced
HFS. The median PFS was 10.6 months vs. 8.2 months
(p <0.0001, HR: 0.86 [95 % CI: 0.81–0.93]) and the
median OS to 28.8 months vs. 24.2 months (p = 0.00038,
HR: 0.85 [95 % CI: 0.77–0.93]) in patients suffering from
HFS CTC grade 1–3 compared to those without this
symptom.
A similar favorable trend could also be observed in
patients who received a capecitabine dose reduction
during therapy, likely associated with the occurrence
of HFS. The median PFS was 10 months vs. 8.3 months
(p = 0.0009, HR: 0.89 [95 % CI: 0.83–0.95]) and the me-
dian OS was 28.6 months vs. 23.8 months (p = 0.0026,
HR: 0.87 [95 % CI: 0.80–0.95]) in patients who received
dose reduction compared to those who did not.
Discussion
The efficacy observed in this observational study is in
the same range as previously reported from randomized
trials. The reported ORR of 35 % mirrors the results
Table 3 Hematological and non-hematological toxicity (maximum pre patient and type)
Toxicity NCI grade 3/4
≤ 75 years >75 years Single agent Combination
Anemia 21 (4 %) 10 (2 %) 22 (4 %) 9 (2 %)
Leukopenia 10 (2 %) 4 (1 %) 1 (0 %) 13 (2 %)
Neutropenia 8 (2 %) 7 (2 %) 2 (0 %) 13 (2 %)
Thrombopenia 12 (2 %) 5 (1 %) 6 (2 %) 11 (2 %)
Nausea 15 (2 %) 9 (2 %) 11 (2 %) 13 (2 %)
Vomiting 8 (2 %) 5 (1 %) 4 (1 %) 9 (2 %)
Diarrhea 24 (4 %) 13 (2 %) 12 (2 %) 26 (4 %)
Mucositis/ stomatitis 4 (1 %) 4 (1 %) 6 (1 %) 3 (1 %)
Bilirubin elevation 16 (3 %) 20 (4 %) 19 (4 %) 27 (5 %)
Neuropathy-motor 13 (2 %) 18 (3 %) 19 (4 %) 14 (3 %)
Hand-foot-syndrome 18 (3 %) 19 (4 %) 21 (4 %) 17 (3 %)
Fever 0 (0 %) 1 (0 %) 1 (0 %) 0 (0 %)
Pain 16 (3 %) 15 (3 %) 13 (2 %) 19 (4 %)
Other 28 (5 %) 19 (3 %) 15 (3 %) 34 (6 %)
Table 4 Tumor response
≤ 75 years >75 years Total
Full analysis set(no. of patients (%))
n 704 533 1237
CR 54 (8 %) 24 (5 %) 78 (6 %)
PR 215 (31 %) 145 (27 %) 360 (29 %)
SD 232 (33 %) 165 (31 %) 397 (32 %)
PD 98 (14 %) 94 (18 %) 192 (16 %)
Insufficient assessment 105 (15 %) 105 (20 %) 210 (17 %)
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obtained in previous single agent or combination trials,
e.g., with oxaliplatin or bevacizumab [6, 9, 16]. The me-
dian PFS results observed compare favorably to prior tri-
als, both for the overall as well as in the different
subgroups regarding age and combination with other
agents. However, these differences may be explained, at
least in part, by the presence of an observation bias due
to a less stringent re-staging schedule in our routine ob-
servation study compared to the randomized trials. With
respect to median overall survival, our results compare
quite favorably to those of the early single drug registra-
tion studies and capecitabine-based doublets [6, 16, 17].
The median OS of 26.1 months observed in our cohort
is likely influenced by the observed shift in median OS
during the last decades due to the availability of new
agents and the increasing integration of locally ablative
procedures. In comparison to former registries in first
line mCRC e.g., BEAT or BRiTE recruited between 2004
and 2006 showing a median OS of up to 23 months the
main recruitment period of this study (60 % of patients
















Progression-free survival by age group
Logrank test: p = 0.00021
75 years: n = 710, 486 events, median = 9.7 months
> 75 years: n = 535, 395 events, median = 8.2 months
≤
Fig. 1 Progression-free survival by age group















Overall survival by age group 
Logrank test: p < 0.0001
≤ 75 years: n = 710, 263 events, median = 31 months
> 75 years: n = 535, 234 events, median = 22.6 months
Fig. 2 Overall survival by age group
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recruited between 2008 and 2011) was later and thus
reflecting more the current developments of a median
OS of about 30 months achieved in current first line tri-
als [18–21]. Furthermore, the patient population seemed
to have a favorable prognosis, in terms of a rather high
rate of a good ECOG PS (0 or 1) despite the median age
of 74 years and the resection of their primary tumor in
the vast majority of patients [22]. Besides increased ORR
(27 vs. 42 %) and median PFS (8.3 vs. 9.8 months,
p = 0.06) comparing single agent and combination
regimen, median OS was similar (25.9 vs. 26.1 months,
p = 0.71). Combination regimen were more often ap-
plied in younger patients (77 % of patients ≤65 years
compared to 26 % of patients >85 years) with likely
more aggressive disease (e.g., higher rate of poorly dif-
ferentiated tumors, multiple metastastic sites).
Regarding toxicity, capecitabine-based regimen can be
administered without major complications in most pa-
tients. The rate of severe toxicities (grade 3 or 4) was
below 5 % with respect to all NCI CTC categories in this
observational study. Hand-foot-syndrome, which proved
to be the dose-limiting toxicity of single drug capecita-
bine, was reported in somewhat less than half of our pa-
tients, but proved to be manageable, with only 3 % of
the patients suffering from serious symptoms.
The treatment efficacy was decreased in the elderly
subgroup (>75 years), but still remained on a high level
with an ORR of 32 %, median PFS of 8.2 months and
OS of 22.6 months. Therefore, the overall efficacy results
of this large group of elderly patients is within the range
as previously reported, considering the relevant number
of elderly patients receiving combination treatment [16,
23, 24]. Moreover, tolerability did not seem to be limited
in elderly patients with regard to grade 3/4 toxicities.
During the last decade treatment approach in elderly
patients has significantly changed, whereas early trials
evaluated only single agent fluoropyrimidines, combin-
ation regimen are currently more frequently adminis-
tered [25–27]. Elderly patients with a good performance
status eligible for clinical phase 3 trials seem to derive a
relevant benefit by the addition of further agents as
shown in different subgroup analyses [28]. Randomized
trials have furthermore established the relevant benefit
and tolerability of combination regimen in elderly pa-
tients [16, 23, 29]. In order to stratify elderly patients to
the different treatment intensities comprehensive geriat-
ric assessment should be applied and is recommended
by current guidelines [30].
Besides, capecitabine has been shown to be well
tolerated and efficacious in elderly patients in the
adjuvant setting as single agent compared to bolus
5FU/LV [31]. In addition, capecitabine (or infusional
5-FU) seems to be the favorable combination partner
if an oxaliplatin-based adjuvant treatment is chosen.
In contrast to prior data including bolus 5FU based
regimen (FLOX), Haller and colleagues recently dem-
onstrated an attenuated but sustained DFS and OS
benefit in elderly patients with a modern fluoropyrimidine
schedule in combination with oxaliplatin (CAPOX or
FOLFOX) [32–34].
Further oral fluoropyrimidines (S-1 or UFT) have been
studied in localized or metastatic CRC, showing toler-
ability and efficacy as single agent or in different combi-
nations (e.g., oxaliplatin – SOX/TEGAFOX regimen or
irinotecan – IRIS/TEGAFIRI) without any apparent
interaction with age [35–39]. Similar to capecitabine,
these oral fluoropyrimidines can be safely combined with
bevacizumab in elderly patients [24, 40]. Recently, TAS
102 has shown a significant survival benefit in heavily
pretreated mCRC patients with good tolerability and
similar OS benefit for patients ≤/>65 years [41].
Dose reductions of capecitabine during treatment does
not lead to a poorer long-term outcome, as previously
reported [42, 43]. However, due to the observational na-
ture of our study, it is not possible to differentiate the ef-
fects of dose modifications from the association with
HFS, the development of which seems to be a strong fa-
vorable prognostic factor by itself. The occurrence of
toxicities like HFS and the consecutive dose reductions
likely are clinical markers of the individual effective dos-
age of capecitabine.
The general characteristics of a non-interventional
study focusing on a specific drug inevitably lead to major
limitations, particularly in regard of bias in terms of pa-
tient selection. An intention-to-treat analysis, was per-
formed with no documented, eligible patient excluded.
However, as inclusion of patients into the observational
study was not entirely under our control, we cannot
completely rule out, that in individual patients with a
very short treatment course (e.g., due to early death), the
record file was not sent to the documentation centre
(although this was clearly not intended or suggested).
Moreover, we cannot control or adjust for any selection
effect that is associated with the decision to use infu-
sional 5-FU instead of the oral alternative. Possibly,
high-risk patients with an immediate need for tumor
shrinkage may be underrepresented. Moreover, decisions
on treatment intensity will likewise be depending on pa-
tients’ age and, thus, subgroup analyses based on these
characteristics are biased by this interdependence. Valid-
ity and completeness of tumor response and toxicity
data is typically lower compared to randomized con-
trolled trials.
Conclusions
Based on the shown efficacy and tolerability, capecitabine
is a valid option for the treatment of colorectal cancer
without any unequivocally apparent age limit.
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